Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Frances R. Balkwill, Stan B. Kaye et al.|Nature reviews. Cancer|2011Cited by 1.5k
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.A. Horwich, SP Stenning, D.Th. Sleijfer et al.|Journal of Clinical Oncology|1997Cited by 334
New perspectives on molecular targeted therapy in ovarian clear cell carcinomaDavid S.P. Tan, Stan B. Kaye, Rowan Miller|British Journal of Cancer|2013Cited by 89
A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodulesBenjamin Hunter, Richard W. Lee, Mitchell Chen et al.|EBioMedicine|2022Cited by 46
Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulationJoaquı́n Mateo, L Rhoda Molife, Michael Friedländer et al.|Unknown|2013Cited by 19